Withdrawal from statins: Implications for secondary stroke prevention and acute treatment

International Journal of Stroke

Volumn 3, Issue 2, 2008, Pages 85-87

  Rodríguez yáñez, Manuel ^a   Dávalos, Antonio ^b   Castillo, José ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RECOMBINANT PLASMINOGEN ACTIVATOR;

ACUTE DRUG ADMINISTRATION; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG MEGADOSE; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; MORTALITY; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SECONDARY PREVENTION; VASODILATATION;

DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECURRENCE; STROKE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 42449163485     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2008.00185.x     Document Type: Article

References (23)

1. Amarenco P, Lavallée P, Touboul PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271-8.
2. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-50.
3. Amarenco P, Bogousslavsky J, Callahan A III; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators et al. High dose atorvastatin after stroke or transient ischaemic attack. New Engl J Med 2006; 355: 549-59.
4. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A: Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23 (Suppl. 2): B72-8.
5. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L: Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007; 13: 208-13.
6. Martí-Fàbregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-21.
7. Zacco A, Togo J, Spence K et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003; 23: 11104-11.
8. Ovbiagele B, Saver JL, Starkman S et al. Statin enhancement of collateralization in acute stroke. Neurology 2007; 68: 2129-31.
9. Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
10. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA Jr, Garcia-Cardena G: Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005; 280: 26714-19.
11. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
12. Chen J, Zhang ZG, Li Y et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53: 743-51.
13. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
14. McGowan MP; Treating to New Target (TNT) Study Group: There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004; 110: 2333-5.
15. Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007; 69: 904-10.
16. Endres M, Laufs U: Discontinuation of statin treatment in stroke patients. Stroke 2006; 37: 2640-3.
17. Ovbiagele B, Saver JL, Fredieu A et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 2004; 35: 2879-83.
18. Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652-7.
19. Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Roh JK: Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: Analysis of risk factors for multifocal signal loss lesions. Stroke 2002; 33: 2845-9.
20. Yano K, Reed DM, MacLean CJ: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989; 20: 1460-5.
21. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5.
22. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E: Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46: 1411-6.
23. Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007; 68: 737-42.